处方药变“瘾品”：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴露“无病历可购药”漏洞，列管与否尚需科学考量

Group 1 - The article highlights the increasing cases of pregabalin abuse in China, particularly among adolescents, with reports of addiction emerging from Hunan and Shanghai in 2025 [4][8][10] - Pregabalin, originally developed by Pfizer for treating epilepsy and neuropathic pain, has seen a rise in misuse since its patent expiration in 2018, with over 50 domestic manufacturers now producing it [4][7] - The ease of online purchasing without proper medical prescriptions has contributed to the accessibility of pregabalin for abuse, especially among youth [10][22][23] Group 2 - Reports indicate that the number of adolescents abusing pregabalin is growing, with cases involving very young individuals, including a 14-year-old girl who required emergency treatment after overdosing [10][11] - The National Narcotics Control Commission has noted a rapid increase in the misuse of controlled substances, with some provinces reporting higher numbers of non-controlled substance abuse than drug abuse [10][15] - The price and availability of pregabalin make it an attractive option for those seeking to misuse substances, especially after the tightening of regulations on other drugs like dextromethorphan [16][25][28] Group 3 - Experts suggest that while pregabalin has not yet been classified as a controlled substance, there is a growing consensus on the need for stricter regulations and monitoring of its prescription and online sales [29][30] - The lack of a unified electronic prescription verification system in online pharmacies poses significant challenges for tracking and managing the misuse of pregabalin [31][32] - Recommendations include implementing a monitoring system for high-risk medications and enhancing the management of online prescriptions to prevent abuse [30][31][32]